Compounds for treating multiple myeloma

A multiple myeloma, compound technology, applied in the field of tenomustine, can solve the problem of toxicity and side effects of chemotherapy

Pending Publication Date: 2021-09-07
MANDIFARMA INTERNESHNL KORPOREJSHN LIMITED
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, chemotherapy often results in severe toxic side effects due to the difficulty in specifically targeting cancer cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for treating multiple myeloma
  • Compounds for treating multiple myeloma
  • Compounds for treating multiple myeloma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0217] A Phase 1 trial including a dose escalation study was conducted to investigate the safety, pharmacokinetic (PK) profile of tenomustine (EDO-S101) in relapsed / refractory hematological malignancies Features and efficacy.

[0218] The patient had a relapsed / refractory hematologic malignancy for which there is currently no available therapy.

[0219] dose escalation level

[0220]

[0221] Dose-limiting toxicities (DLTs) were assessed based on Cycle 1 events only. Toxicity was assessed with respect to type and severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (June 2010). Toxicity data were collected for all patients throughout their study period. Infusion site reactions were assessed using the Phlebitis Scale developed by the Association of Infusion Nurses (2011).

[0222] DLTs that are at least potentially related to study drug are defined as:

[0223] Any grade 3 or 4 non-hematological toxicit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to tinostamustine for use in the treatment of multiple myeloma. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

Description

technical field [0001] The present invention relates to tinostamustine for use in the treatment of multiple myeloma. [0002] Background of the invention [0003] Multiple myeloma is a cancer of plasma cells. Normal plasma cells produce immunoglobulins to fight infection. In myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody -- called paraprotein -- that has no useful function. It tends to accumulate in the bone marrow and circulates in the blood, and can also be detected in the urine. It affects multiple sites in the body (hence "multiple myeloma") where the bone marrow is normally active in adults. The major forms of multiple myeloma (or as it is also called myeloma) are active myeloma, plasmacytoma, light chain myeloma, and nonsecretory myeloma. The number of new cases of myeloma in the United States in 2011 was 6.1 per 100,000 men and women per year, and the percent survival beyond five years was 45%. It is estimated ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4184A61P35/00
CPCA61K31/4184A61P35/00A61P7/00G16H20/10A61K9/0019A61K45/06
Inventor 卡塔里纳·希尔吉尔弗朗西斯科·伊巴内斯·洛佩兹托马斯·乔·梅林
Owner MANDIFARMA INTERNESHNL KORPOREJSHN LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap